Immunological characterization of the early human fracture hematoma

Immunologic Research

Volumn 64, Issue 5-6, 2016, Pages 1195-1206

  Hoff, Paula ^a,b,c   Gaber, T ^a,b,c   Strehl, C ^a,b   Schmidt Bleek, K ^a   Lang, A ^a,b,d   Huscher, D ^a,b   Burmester, G R ^a,b   Schmidmaier, G ^e   Perka, C ^a,c   Duda, G N ^a,c   Buttgereit, F ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^d Berlin Brandenburg School for Regenerative Therapies (BSRT)   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bone healing; Cytokines; Fracture healing; Fracture hematoma; Immune function; Inflammation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; CYTOKINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CELL SURVIVAL; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; FRACTURE; FRACTURE HEALING; FRACTURE HEMATOMA; GRANULOCYTE; HELPER CELL; HEMATOMA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; BONE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; CELL MOVEMENT; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; CYTOKINES; FEMALE; FLOW CYTOMETRY; FRACTURES, BONE; GRANULOCYTES; HEMATOMA; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84987650369     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-016-8868-9     Document Type: Article

References (55)

1. Kolar P, Schmidt-Bleek K, Schell H, Gaber T, Toben D, Schmidmaier G, et al. The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev. 2010;16(4):427–34.
2. Park JE, Barbul A. Understanding the role of immune regulation in wound healing. Am J Surg. 2004;187(5A):11S–6S.
3. Epari DR, Kassi JP, Schell H, Duda GN. Timely fracture-healing requires optimization of axial fixation stability. J Bone Joint Surg Am. 2007;89(7):1575–85.
4. Schell H, Lienau J, Epari DR, Seebeck P, Exner C, Muchow S, et al. Osteoclastic activity begins early and increases over the course of bone healing. Bone. 2006;38(4):547–54.
5. Park SH, Silva M, Bahk WJ, McKellop H, Lieberman JR. Effect of repeated irrigation and debridement on fracture healing in an animal model. J Orthop Res. 2002;20(6):1197–204.
6. Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508(7495):269–73.
7. Brighton CT, Krebs AG. Oxygen tension of healing fractures in the rabbit. J Bone Joint Surg Am. 1972;54(2):323–32.
8. Brighton CT, Krebs AG. Oxygen tension of nonunion of fractured femurs in the rabbit. Surg Gynecol Obstet. 1972;135(3):379–85.
9. Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. Hypoxia inducible factor (HIF) in rheumatology: low O2! see what HIF can do! Ann Rheum Dis. 2005;64(7):971–80.
10. Kolar P, Gaber T, Perka C, Duda GN, Buttgereit F. Human early fracture hematoma is characterized by inflammation and hypoxia. Clin Orthop Relat Res. 2011;469(11):3118–26 (Epub 2011/03/17).
11. Hoff P, Gaber T, Schmidt-Bleek K, Senturk U, Tran CL, Blankenstein K, et al. Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomas. Immunol Res. 2011;51(1):116–22 (Epub 2011/07/02).
12. Hoff P, Maschmeyer P, Gaber T, Schutze T, Raue T, Schmidt-Bleek K, et al. Human immune cells’ behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model. Cell Mol Immunol. 2013;10(2):151–8 (Epub 2013/02/12).
13. Hoff P, Rakow A, Gaber T, Hahne M, Senturk U, Strehl C, et al. Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans. Bone. 2013;55(1):93–101 (Epub 2013/04/11).
14. Canturk NZ, Esen N, Vural B, Canturk Z, Kirkali G, Oktay G, et al. The relationship between neutrophils and incisional wound healing. Skin Pharmacol Appl Skin Physiol. 2001;14(2):108–16.
15. Bastian OW, Koenderman L, Alblas J, Leenen LP, Blokhuis TJ. Neutrophils contribute to fracture healing by synthesizing fibronectin + extracellular matrix rapidly after injury. Clin Immunol. 2016;164:78–84.
16. Simpson DM, Ross R. The neutrophilic leukocyte in wound repair a study with antineutrophil serum. J Clin Investig. 1972;51(8):2009–23.
17. Schaffer M, Barbul A. Lymphocyte function in wound healing and following injury. Br J Surg. 1998;85(4):444–60.
18. Xing Z, Lu C, Hu D, Yu YY, Wang X, Colnot C, et al. Multiple roles for CCR2 during fracture healing. Dis Model Mech. 2010;3(7–8):451–8 (Epub 2010/04/01).
19. Chan JK, Glass GE, Ersek A, Freidin A, Williams GA, Gowers K, et al. Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response. EMBO Mol Med. 2015;7(5):547–61.
20. Kawakami Y, Ii M, Alev C, Kawamoto A, Matsumoto T, Kuroda R, et al. Local transplantation of ex vivo expanded bone marrow-derived CD34-positive cells accelerates fracture healing. Cell Transplant. 2012;21(12):2689–709 (Epub 2012/09/05).
21. Kuroda R, Matsumoto T, Kawakami Y, Fukui T, Mifune Y, Kurosaka M. Clinical impact of circulating CD34-positive cells on bone regeneration and healing. Tissue Eng Part B Rev. 2014;20(3):190–9.
22. Fukui T, Mifune Y, Matsumoto T, Shoji T, Kawakami Y, Kawamoto A, et al. Superior potential of CD34-positive cells compared to total mononuclear cells for healing of nonunion following bone fracture. Cell Transpl. 2015;24(7):1379–93.
23. Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood. 2001;97(7):1920–4 (Epub 2001/03/27).
24. Konnecke I, Serra A, El Khassawna T, Schlundt C, Schell H, Hauser A, et al. T and B cells participate in bone repair by infiltrating the fracture callus in a two-wave fashion. Bone. 2014;64:155–65 (Epub 2014/04/12).
25. Toben D, Schroeder I, El Khassawna T, Mehta M, Hoffmann JE, Frisch JT, et al. Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res. 2011;26(1):113–24 (Epub 2010/07/20).
26. Reinke S, Geissler S, Taylor WR, Schmidt-Bleek K, Juelke K, Schwachmeyer V, et al. Terminally differentiated CD8(+) T cells negatively affect bone regeneration in humans. Sci Transl Med. 2013;5(177):177.
27. Lange J, Sapozhnikova A, Lu C, Hu D, Li X, Miclau T 3rd, et al. Action of IL-1beta during fracture healing. J Orthop Res. 2010;28(6):778–84 (Epub 2009/12/31).
28. Mumme M, Scotti C, Papadimitropoulos A, Todorov A, Hoffmann W, Bocelli-Tyndall C, et al. Interleukin-1beta modulates endochondral ossification by human adult bone marrow stromal cells. Eur Cell Mater. 2012;24:224–36 (Epub 2012/09/26).
29. Hengartner NE, Fiedler J, Ignatius A, Brenner RE. IL-1beta inhibits human osteoblast migration. Mol Med. 2013;19:36–42 (Epub 2013/03/20).
30. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol. 1998;160(11):5347–54.
31. Hauser CJ, Zhou X, Joshi P, Cuchens MA, Kregor P, Devidas M, et al. The immune microenvironment of human fracture/soft-tissue hematomas and its relationship to systemic immunity. J Trauma. 1997;42(5):895–903.
32. Currie HN, Loos MS, Vrana JA, Dragan K, Boyd JW. Spatial cytokine distribution following traumatic injury. Cytokine. 2014;66(2):112–8 (Epub 2014/01/28).
33. Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J. TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci USA. 2011;108(4):1585–90 (Epub 2011/01/07).
34. Holbrook ST, Ohls RK, Schibler KR, Yang YC, Christensen RD. Effect of interleukin-9 on clonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors. Blood. 1991;77(10):2129–34 (Epub 1991/05/15).
35. Ikemizu S, Chirifu M, Davis SJ. IL-2 and IL-15 signaling complexes: different but the same. Nat Immunol. 2012;13(12):1141–2 (Epub 2012/11/20).
36. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA. 2004;101(7):1969–74 (Epub 2004/02/06).
37. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595–601 (Epub 2006/07/27).
38. Schmidt-Bleek K, Schell H, Lienau J, Schulz N, Hoff P, Pfaff M, et al. Initial immune reaction and angiogenesis in bone healing. J Tissue Eng Regen Med. 2014;8(2):120–30.
39. Silfversward CJ, Sisask G, Larsson S, Ohlsson C, Frost A, Ljunggren O, et al. Bone formation in interleukin-4 and interleukin-13 depleted mice. Acta Orthop. 2008;79(3):410–20 (Epub 2008/07/16).
40. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta. 2010;411(21–22):1570–9 (Epub 2010/07/17).
41. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36(10):1882–6 (Epub 2004/06/19).
42. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol. 2001;2(2):102–7 (Epub 2001/03/29).
43. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30(3):245–57 (Epub 2010/07/29).
44. Wu AC, Morrison NA, Kelly WL, Forwood MR. MCP-1 expression is specifically regulated during activation of skeletal repair and remodeling. Calcif Tissue Int. 2013;92(6):566–75 (Epub 2013/03/06).
45. Ishida K, Matsumoto T, Sasaki K, Mifune Y, Tei K, Kubo S, et al. Bone regeneration properties of granulocyte colony-stimulating factor via neovascularization and osteogenesis. Tissue Eng Part A. 2010;16(10):3271–84 (Epub 2010/07/16).
46. Hogan SP. Recent advances in eosinophil biology. Int Arch Allergy Immunol. 2007;143(Suppl 1):3–14 (Epub 2007/08/09).
47. Pease JE. Asthma, allergy and chemokines. Curr Drug Targets. 2006;7(1):3–12 (Epub 2006/02/04).
48. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168(7):3195–204 (Epub 2002/03/22).
49. Kaplan AP. Chemokines, chemokine receptors and allergy. Int Arch Allergy Immunol. 2001;124(4):423–31 (Epub 2001/05/08).
50. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100(6):2195–202 (Epub 2002/08/30).
51. Detsch R, Boccaccini AR. The role of osteoclasts in bone tissue engineering. J Tissue Eng Regen Med. 2015;9(10):1133–49.
52. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270(5243):1811–5 (Epub 1995/12/15).
53. Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation. Expert Opin Ther Targets. 2013;17(12):1439–60 (Epub 2013/10/05).
54. Chim SM, Tickner J, Chow ST, Kuek V, Guo B, Zhang G, et al. Angiogenic factors in bone local environment. Cytokine Growth Factor Rev. 2013;24(3):297–310 (Epub 2013/04/25).
55. Clarkin CE, Gerstenfeld LC. VEGF and bone cell signalling: an essential vessel for communication? Cell Biochem Funct. 2013;31(1):1–11 (Epub 2012/11/07).